Department of Experimental Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN 55905, USA.
Cancer Metab. 2014 Aug 18;2:13. doi: 10.1186/2049-3002-2-13. eCollection 2014.
Loss of the endosulfatase HSulf-1 is common in ovarian cancer, upregulates heparin binding growth factor signaling and potentiates tumorigenesis and angiogenesis. However, metabolic differences between isogenic cells with and without HSulf-1 have not been characterized upon HSulf-1 suppression in vitro. Since growth factor signaling is closely tied to metabolic alterations, we determined the extent to which HSulf-1 loss affects cancer cell metabolism.
Ingenuity pathway analysis of gene expression in HSulf-1 shRNA-silenced cells (Sh1 and Sh2 cells) compared to non-targeted control shRNA cells (NTC cells) and subsequent Kyoto Encyclopedia of Genes and Genomics (KEGG) database analysis showed altered metabolic pathways with changes in the lipid metabolism as one of the major pathways altered inSh1 and 2 cells. Untargeted global metabolomic profiling in these isogenic cell lines identified approximately 338 metabolites using GC/MS and LC/MS/MS platforms. Knockdown of HSulf-1 in OV202 cells induced significant changes in 156 metabolites associated with several metabolic pathways including amino acid, lipids, and nucleotides. Loss of HSulf-1 promoted overall fatty acid synthesis leading to enhance the metabolite levels of long chain, branched, and essential fatty acids along with sphingolipids. Furthermore, HSulf-1 loss induced the expression of lipogenic genes including FASN, SREBF1, PPARγ, and PLA2G3 stimulated lipid droplet accumulation. Conversely, re-expression of HSulf-1 in Sh1 cells reduced the lipid droplet formation. Additionally, HSulf-1 also enhanced CPT1A and fatty acid oxidation and augmented the protein expression of key lipolytic enzymes such as MAGL, DAGLA, HSL, and ASCL1. Overall, these findings suggest that loss of HSulf-1 by concomitantly enhancing fatty acid synthesis and oxidation confers a lipogenic phenotype leading to the metabolic alterations associated with the progression of ovarian cancer.
Taken together, these findings demonstrate that loss of HSulf-1 potentially contributes to the metabolic alterations associated with the progression of ovarian pathogenesis, specifically impacting the lipogenic phenotype of ovarian cancer cells that can be therapeutically targeted.
在内分泌硫酯酶 HSulf-1 缺失是卵巢癌的常见现象,它上调肝素结合生长因子信号,增强肿瘤发生和血管生成。然而,在体外抑制 HSulf-1 时,具有和不具有 HSulf-1 的同基因细胞之间的代谢差异尚未得到描述。由于生长因子信号与代谢改变密切相关,我们确定了 HSulf-1 缺失对癌细胞代谢的影响程度。
HSulf-1 shRNA 沉默细胞(Sh1 和 Sh2 细胞)与非靶向对照 shRNA 细胞(NTC 细胞)的基因表达的 IPA 通路分析,以及随后京都基因与基因组百科全书(KEGG)数据库分析显示,脂质代谢发生变化是 Sh1 和 2 细胞中改变的主要途径之一。在这些同基因细胞系中,使用 GC/MS 和 LC/MS/MS 平台对非靶向全局代谢组学进行了分析,共鉴定出约 338 种代谢物。在 OV202 细胞中敲低 HSulf-1 会导致与几种代谢途径相关的 156 种代谢物发生显著变化,包括氨基酸、脂质和核苷酸。HSulf-1 的缺失促进了整体脂肪酸合成,导致长链、支链和必需脂肪酸以及神经酰胺的代谢物水平升高。此外,HSulf-1 缺失诱导了包括 FASN、SREBF1、PPARγ 和 PLA2G3 在内的脂生成基因的表达,刺激了脂滴的积累。相反,在 Sh1 细胞中重新表达 HSulf-1 会减少脂滴的形成。此外,HSulf-1 还增强了 CPT1A 和脂肪酸氧化,并增加了关键脂肪酶如 MAGL、DAGLA、HSL 和 ASCL1 的蛋白表达。总的来说,这些发现表明,HSulf-1 的缺失通过同时增强脂肪酸合成和氧化赋予了一种生脂表型,导致与卵巢癌进展相关的代谢改变。
综上所述,这些发现表明,HSulf-1 的缺失可能导致与卵巢癌发病机制进展相关的代谢改变,特别是影响卵巢癌细胞的生脂表型,这可以作为治疗靶点。